Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: Disease and staging biomarkers and new drug targets

Neuroscience Letters

Volumn 617, Issue , 2016, Pages 66-71

  de Farias, Carine Coneglian ^a   Maes, Michael ^a,b   Bonifácio, Kamila Landucci ^a   Bortolasci, Chiara Cristina ^a   de Souza Nogueira, André ^a   Brinholi, Francis Fregonesi ^a   Matsumoto, Andressa Keiko ^a   do Nascimento, Matheus Amarante ^a   de Melo, Lúcio Baena ^a   Nixdorf, Suzana Lucy ^a   Lavado, Edson Lopes ^a   Moreira, Estefânia Gastaldello ^a   Barbosa, Décio Sabbatini ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

Antioxidants; Malondialdehyde; Oxidative stress; Parkinson disease; Staging

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; NITRIC OXIDE;

AGED; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; METABOLISM; MIDDLE AGED; PARKINSON DISEASE; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; ANTIOXIDANTS; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; NITRIC OXIDE; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84958211385     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.02.011     Document Type: Article

References (30)

1. Anderson G., Maes M. Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins. Mol. Neurobiol. 2014, 49:771-783. 10.1007/s12035-013-8554-z.
2. Gandhi S., Abramov A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell. Longev. 2012, 2012. 10.1155/2012/428010.
3. Nikam S., Nikam P., Ahaley S.K., Sontakke A.V. Oxidative stress in Parkinson's disease. Indian J. Clin. Biochem. 2009, 24:98-101.
4. Zhou C., Huang Y., Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann. N. Y. Acad. Sci. 2016, 2008:93-104. 10.1196/annals.1427.023.
5. Sharma A., Kaur P., Kumar B., Prabhakar S., Gill K.D. Plasma lipid peroxidation and antioxidant status of Parkinson's disease patients in the Indian population. Parkinsonism Relat. Disord. 2008, 14:52-57. 10.1016/j.parkreldis.2007.06.009.
6. Taylor J.M., Main B.S., Crack P.J. Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem. Int. 2013, 62:803-819. 10.1016/j.neuint.2012.12.016.
7. Ikeda K., Nakamura Y., Kiyozuka T., Aoyagi J., Hirayama T., Nagata R., et al. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression. Neurodegener. Dis. 2011, 8:252-258. 10.1159/000323265.
8. Belin A.C., Ran C., Anvret A., Paddock S., Westerlund M., Håkansson A., et al. Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease. Neurosci. Lett. 2012, 522:30-35. 10.1016/j.neulet.2012.06.007.
9. Benmoyal-Segal L., Vander T., Shifman S., Bryk B., Ebstein R.P., Marcus E.-L., et al. Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. FASEB J. 2005, 19:452-454. 10.1096/fj.04-2106fje.
10. Andican G., Konukoglu D., Bozluolcay M., Bayülkem K., Firtiina S., Burcak G. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson's disease. Acta Neurol. Belg. 2012, 112:155-159. 10.1007/s13760-012-0015-3.
11. Hassin-Baer S., Cohen O.S., Vakil E., Molshazki N., Sela B.A., Nitsan Z., et al. Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson's disease?. J. Neural Transm. 2011, 118:539-543. 10.1007/s00702-010-0535-z.
12. Repetto M., Reides C., Gomez Carretero M.L., Costa M., Griemberg G., Llesuy S. Oxidative stress in blood of HIV infected patients. Clin. Chim. Acta 1996, 255:107-117.
13. 2+ in the presence of xylenol orange. Comparison with the TBA assay and an iodometric method. Lipids 1991, 26:853-856. 10.1007/BF02536169.
14. Gonzalez Flecha B., Llesuy S., Boveris A. Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver, and muscle. Free Radic. Biol. Med. 1991, 10:93-100. 10.1016/0891-5849(91)90002-K.
15. Bastos A.S., Loureiro A.P.D.M., De Oliveira T.F., Corbi S.C.T., Caminaga R.M.S., Rossa C., et al. Quantitation of malondialdehyde in gingival crevicular fluid by a high-performance liquid chromatography-based method. Anal. Biochem. 2012, 423:141-146. 10.1016/j.ab.2012.01.016.
16. Navarro-Gonzálvez J.A., García-Benayas C., Arenas J. Semiautomated measurement of nitrate in biological fluids. Clin. Chem. 1998, 44:679-681.
17. Marklund S., Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 1974, 47:469-474. 10.1111/j.1432-1033.1974.tb03714.x.
18. Aebi H. [13] catalase in vitro. Methods Enzymol. 1984, 105:121-126. 10.1016/S0076-6879(84)05016-3.
19. Hu M.L. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 1994, 233:380-385. 10.1016/S0076-6879(94)33044-1.
20. Richter R.J., Jarvik G.P., Furlong C.E. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ. Cardiovasc. Genet. 2008, 1:147-152. 10.1161/CIRCGENETICS.108.811638.
21. Serra J.A., Domínguez R.O., De Lustig E.S., Guareschi E.M., Famulari A.L., Bartolomé E.L., et al. Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J. Neural Transm. 2001, 108:1135-1148. 10.1007/s007020170003.
22. Su X., Federoff H.J. Immune responses in parkinson's disease: interplay between central and peripheral immune systems. Biomed. Res. Int. 2014, 2014. 10.1155/2014/275178.
23. Moylan S., Berk M., Dean O.M., Samuni Y., Williams L., O'Neil A., et al. Oxidative & nitrosative stress in depression: why so much stress?. Neurosci Biobehav. Rev. 2014, 45:46-62. 10.1016/j.neubiorev.2014.05.007.
24. Serra J.A., Domínguez R.O., Marschoff E.R., Guareschi E.M., Famulari A.L., Boveris A. Systemic oxidative stress associated with the neurological diseases of aging. Neurochem. Res. 2009, 34:2122-2132. 10.1007/s11064-009-9997-5.
25. Yuan R.Y., Wu M.-Y., Hu S.-P. Antioxidant status in patients with Parkinson's disease. Nutr. Res. 2000, 20:647-652. 10.1016/S0271-5317(00)00154-8.
26. Abraham S., Soundararajan C.C., Vivekanandhan S., Behari M. Erythrocyte antioxidant enzymes in Parkinson's disease. Indian J. Med. Res. 2005, 111-115.
27. Morris G., Maes M. Oxidative and nitrosative stress and immune-inflammatory pathways in patients with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Curr. Neuropharmacol. 2014, 12:168-185. 10.2174/1570159X11666131120224653.
28. Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. Mol. Neurobiol. 2014, 49:28-38. 10.1007/s12035-013-8483-x.
29. Zeng B.Y., Pearce R.K., MacKenzie G.M., Jenner P. Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-or D-receptor in the striatum of normal monkeys: an autoradiographic study. J. Neural Transm. 2001, 108:925-941. 10.1007/s007020170013.
30. Chen C.M., Liu J.L., Wu Y.R., Chen Y.C., Cheng H.S., Cheng M.L., et al. Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiol. Dis. 2009, 33:429-435. 10.1016/j.nbd.2008.11.011.